CN106074696A - A kind of health product being improved immunity of organisms and anti-fatigue effect by regulation and control content of nitric oxide technology - Google Patents
A kind of health product being improved immunity of organisms and anti-fatigue effect by regulation and control content of nitric oxide technology Download PDFInfo
- Publication number
- CN106074696A CN106074696A CN201610565218.0A CN201610565218A CN106074696A CN 106074696 A CN106074696 A CN 106074696A CN 201610565218 A CN201610565218 A CN 201610565218A CN 106074696 A CN106074696 A CN 106074696A
- Authority
- CN
- China
- Prior art keywords
- effect
- organisms
- immunity
- parts
- health product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000694 effects Effects 0.000 title claims abstract description 48
- 230000036541 health Effects 0.000 title claims abstract description 40
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title claims abstract description 37
- 230000036039 immunity Effects 0.000 title claims abstract description 33
- 230000002929 anti-fatigue Effects 0.000 title claims abstract description 21
- 230000033228 biological regulation Effects 0.000 title claims abstract description 12
- 238000005516 engineering process Methods 0.000 title claims abstract description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 24
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 22
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000002994 raw material Substances 0.000 claims abstract description 20
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 14
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 12
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 12
- 239000011718 vitamin C Substances 0.000 claims abstract description 12
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims abstract description 11
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 11
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960002173 citrulline Drugs 0.000 claims abstract description 11
- 235000013477 citrulline Nutrition 0.000 claims abstract description 11
- 235000019152 folic acid Nutrition 0.000 claims abstract description 11
- 229960000304 folic acid Drugs 0.000 claims abstract description 11
- 239000011724 folic acid Substances 0.000 claims abstract description 11
- 229960003080 taurine Drugs 0.000 claims abstract description 11
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229940046009 vitamin E Drugs 0.000 claims abstract description 7
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 7
- 239000011709 vitamin E Substances 0.000 claims abstract description 7
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 claims description 12
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 10
- 229930064664 L-arginine Natural products 0.000 claims description 10
- 235000014852 L-arginine Nutrition 0.000 claims description 10
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 7
- 229930003944 flavone Natural products 0.000 claims description 7
- 150000002212 flavone derivatives Chemical class 0.000 claims description 7
- 235000011949 flavones Nutrition 0.000 claims description 7
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 7
- 229930183118 Tanshinone Natural products 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 201000010099 disease Diseases 0.000 abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 210000004185 liver Anatomy 0.000 abstract description 10
- 210000003734 kidney Anatomy 0.000 abstract description 9
- 239000004475 Arginine Substances 0.000 abstract description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract description 5
- 230000001681 protective effect Effects 0.000 abstract description 5
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 3
- 230000036772 blood pressure Effects 0.000 abstract description 3
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 230000005784 autoimmunity Effects 0.000 abstract description 2
- 230000004531 blood pressure lowering effect Effects 0.000 abstract description 2
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- 229960003121 arginine Drugs 0.000 abstract 1
- 239000000047 product Substances 0.000 description 32
- 241000699670 Mus sp. Species 0.000 description 19
- 238000012360 testing method Methods 0.000 description 18
- 206010016256 fatigue Diseases 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 229960003753 nitric oxide Drugs 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- 230000009182 swimming Effects 0.000 description 10
- 239000002253 acid Substances 0.000 description 7
- 102100026189 Beta-galactosidase Human genes 0.000 description 6
- 108010059881 Lactase Proteins 0.000 description 6
- 108010005774 beta-Galactosidase Proteins 0.000 description 6
- 230000035487 diastolic blood pressure Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 229940116108 lactase Drugs 0.000 description 6
- 108010006464 Hemolysin Proteins Proteins 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000003228 hemolysin Substances 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 4
- 229920002527 Glycogen Polymers 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 4
- 235000009697 arginine Nutrition 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 229940096919 glycogen Drugs 0.000 description 4
- 230000008588 hemolysis Effects 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 210000003024 peritoneal macrophage Anatomy 0.000 description 4
- 230000008782 phagocytosis Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000034659 glycolysis Effects 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 208000033065 inborn errors of immunity Diseases 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 235000021590 normal diet Nutrition 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102100032252 Antizyme inhibitor 2 Human genes 0.000 description 1
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101000798222 Homo sapiens Antizyme inhibitor 2 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000219422 Urtica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008799 immune stress Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a kind of health product being improved immunity of organisms and anti-fatigue effect by regulation and control content of nitric oxide technology, it is made up according to certain weight proportion of L arginine, citrulline, taurine, vitamin C, vitamin E, folic acid, Herba Apocyni veneti extract, the raw material of Radix Salviae Miltiorrhizae extract.Raw materials used effect with mutual Synergistic of this product, it is remarkably improved immunity of organism effect and anti-fatigue ability, having instant, safety and Health, be easy to carry and long-term taking, the feature of stable curative effect, its immunity improves effect and is significantly higher than the effect of any one-component；The most also there is significant blood pressure lowering effect; too increase the body self resistance to disease while blood pressure lowering, be very suitable for modern sub-health population and hyperpietic's use and raising and dirty the playing of Liver and kidney for Patients with Cardiovascular/Cerebrovascular Diseases autoimmunity are repaired and protective effect.
Description
Technical field
The present invention relates to a kind of health product, specifically one and improve body by regulation and control content of nitric oxide technology
Immunity and the health product of anti-fatigue effect.
Background technology
Immunity is the defense mechanism of human body self, is human bioequivalence and elimination exotic invasive foreign body, processes old and feeble, damage
Wound, dead, the own cells of degeneration and identification and process vivo mutations cell and the ability of virus infected cell.Modern immunity
Think, immunity is human bioequivalence and the physiological reaction getting rid of " dissident ".Hypoimmunity then immune system can not normally be sent out
Waving protective effect, in the case, easily infected by antibacterial, virus, fungus etc., therefore hypoimmunity just the most directly shows
It is liable to illness.Frequent sick meeting increases the weight of the consumption of body, thus typically have a delicate constitution, malnutrition, lethargy, tired
Unable, appetite reduction, sleep disorder etc., disease Chang Fanfu such as flu, tonsillitis, asthma, bronchitis, pneumonia, diarrhoea is sent out
Making, each persistent period is long, and teenager body development if things go on like this can be caused bad, and adult the most easily induces major disease.
Tired (fatigue) is the physiological acoustic signals process of a kind of complexity of body.Physical fatigue be due to motion or
Physical work and cause organism physiology process can not by its function continue can not maintain it at each organ of a specified level or body
The phenomenon of original function level.Its generation is reminded worker should lower working strength or terminates motion in order to avoid body injury.?
When carrying out over loading physical exertion, muscle group persistently or exceedingly shrinks, the energy substance in a large amount of consumer of meeting, produces breast
The metabolites (medically known as ponogen) such as acid, carbon dioxide, water, the acidity in blood also can increase.When these metabolism are produced
Thing gather a certain amount of after, so that it may affect the telescopic movable of muscle, and stimulate cerebral central nervous system, make people produce tired nothing
The uncomfortable sensations such as power, irritated unhappy, sleepy, muscular soreness, anorexia, work lose interest, health tires out to make people feel, muscle power is tired
Labor the most just creates.
The incidence rate of the subhealth state such as hypoimmunity, fatigue is in the trend constantly risen in recent years, and is prevalent in each
The crowd of individual age bracket, it by global extensive concern, will become 2l century human health to the impact of human health
Formidable enemy.Although subhealth state is not a kind of clear and definite organic disease, but it is the unsound performance of modern's body and mind after all, is device matter
Property disease omen, some reflecting body to a certain extent are abnormal.Subhealth state has become and has a strong impact on human health, leads
Cause one of pathogenetic key factor of disease.For preventing trouble before it happens, World Health Organization (WHO) proposes to carry out " preventative health policy ",
Sub-health state is carried out keypoint control, prevention, elimination subhealth state are set to the preventative of an emphasis enforcement in 2l century and are good for
Health strategy, and then improve the health level of the whole mankind.At present, the product market of China's enhancing immunity based on medicine, hormone,
Account for the 60% of whole market share；Health food is auxiliary, accounts for 35%, and other account for 15%.Although medicine effect is more apparent, but
Drug resistance that long-term prescription causes, Drug resistance, lesions of liver and kidney etc. may produce infringement to consumer.Additionally, due to medicine will be
Taking under the guidance of doctor, health food is the most different, and it not only has the health care merit of enhancing immunity and alleviating physical fatigue
Can, and to human non-toxic's side effect, can take according to being actually needed of oneself.Therefore, occur on market in recent years many
There are the health product of enhancing immunity, but health-care effect is uneven.
Summary of the invention
For problems of the prior art, the invention provides one and carried by regulation and control content of nitric oxide technology
High immunity of organisms and the health product of anti-fatigue effect.These health product are with L-arginine, citrulline, taurine, vitamin C, dimension
Raw element E, folic acid, Herba Apocyni veneti extract, Radix Salviae Miltiorrhizae extract are primary raw material, and the conventional adjuvant being aided with on pharmaceutics is prepared as routine
Pharmaceutical formulation, each material combination is scientific and reasonable, complements each other, and has the effect of Synergistic, has the body that increases significantly and resists
Condition of disease power, enhancing human body immunity, the effect of resisting fatigue, hyperpietic can also be had preferable therapeutic effect, tool simultaneously
There is the feature of instant, safety, stable curative effect.
The present invention is by the following technical solutions:
A kind of health product being improved immunity of organisms and anti-fatigue effect by regulation and control content of nitric oxide technology, it is
It is made up of the raw material of following weight portion: L-arginine 100-150 part, citrulline 10-30 part, taurine 8-15 part, vitamin C
0.3-0.8 part, vitamin E 0.3-0.5 part, folic acid 1-2 part, Herba Apocyni veneti extract 10-20 part, Radix Salviae Miltiorrhizae extract 20-30 part.
Preferably, described improving immunity of organisms and the health product of anti-fatigue effect, it is former by following weight portion
Material is made: L-arginine 130 parts, citrulline 20 parts, taurine 12 parts, vitamin C 0.5 part, vitamin E 0.4 part, folic acid
1.5 parts, Herba Apocyni veneti extract 15 parts, Radix Salviae Miltiorrhizae extract 25 parts.
Preferably, in described Radix Salviae Miltiorrhizae extract, total tanshinone content is 10-20%.
Preferably, described Herba Apocyni veneti extract general flavone content is 30-50%.
Preferably, described improves immunity of organisms and the health product of anti-fatigue effect, after described each raw material weighs according to quantity,
Conventionally add adjuvant conventional on pharmaceutics and be prepared as capsule, tablet, powder or pill.
L-arginine in prescription of the present invention, citrulline, taurine, vitamin E, vitamin C, folic acid with the use of, have
Significantly alleviating physical fatigue, effect of raising immunity of organisms, wherein vitamin C, vitamin E guarantees one as antioxidant
Nitrogen oxide biological activity, it is possible to remove free radical, eliminates side effect.Modern study finds, for old cardiovascular disease patient,
Hepatic and kidney function obstacle even liver and kidney failure often occurs, is excessively used arginine for a long time and may increase the weight of Liver and kidney burden.Now
Body participates in arginase and the arginine decarboxylase decline of arginine metabolism, and nitricoxide synthase (NOS) rises, and supplements
Arginine is likely to result in body and produces too much nitric oxide (NO), causes primary cellular defect and immunological stress, is unfavorable for maintenance machine
Homoiostasis.The NO of low dosage have improve Tissue Blood for, reduce platelet adhesion reaction, suppression inflammatory reaction, promote albumen
The beneficial effects such as matter synthesis and acceleration wound repair.And the NO of high dose is while immune cell activated, generation can be induced big
Amount inflammatory mediator and free radical, promote inflammatory reaction, increase the weight of tissue injury.Thus, the multiformity of Effect of Nitric Oxide makes disease
In prevention and clinical treatment, arginine has the effect of " double-edged sword ", uses and appropriately can improve therapeutic effect, improper use, on the contrary
Increase the weight of infringement, run counter to desire.And prescription of the present invention is also aided with Herba Apocyni veneti extract and Radix Salviae Miltiorrhizae extract, Herba Apocyni veneti therein carries
Take thing general flavone content between 30-50%, it is possible to Reasonable Regulation And Control body intracellular nitric oxide content, it is possible to substantially reduce growth thin
Intracellular cytokine and inflammatory factor level, produce protective effect, and then protection kidney to kidney cell；Radix Salviae Miltiorrhizae extract then can be bright
Show and improve liver microcirculation, further the liver protecting.Thus the prescription compatibility of the present invention uses and is remarkably improved immunity of organism
And resisting fatigue, for most of senile cardio cerebrovascular disease patients, the Liver and kidney that will not cause because of excessive use is dirty
Damage further, each material composition effect is complemented each other, on the basis of improving immunity of organisms and fatigue alleviating, also to Liver and kidney
Dirty play a protective role.Additionally, the product of the present invention is while having resisting fatigue and improving immunity effect, also have substantially
Blood pressure reduction effect, can assist for the treatment to hyperpietic.
The invention has the beneficial effects as follows: raw materials used effect with mutual Synergistic of this product, be remarkably improved machine
Body resistance against diseases, enhancing immune effect, have instant, safety and Health, be easy to carry and long-term taking, the spy of stable curative effect
Point, its immunity improves effect and is significantly higher than the effect of any one-component；The most also there is significant blood pressure lowering effect, be suitable for
Hypertensive patient uses, and too increases the body self resistance to disease while blood pressure lowering, is very suitable for modern sub-strong
Kang Renqun and hyperpietic's use and raising and dirty the playing of Liver and kidney for Patients with Cardiovascular/Cerebrovascular Diseases autoimmunity repair
Answer and protective effect.
Detailed description of the invention
Below in conjunction with specific embodiment, present disclosure is described in further detail.
Embodiment 1
A kind of health product being improved immunity of organisms and anti-fatigue effect by regulation and control content of nitric oxide technology, it is
It is made up of the raw material of following weight portion: L-arginine 100 parts, citrulline 10 parts, taurine 8 parts, vitamin C 0.3 part, dimension are raw
Element E 0.3 part, 1 part of folic acid, Herba Apocyni veneti extract 10 parts, Radix Salviae Miltiorrhizae extract 20 parts.In described Radix Salviae Miltiorrhizae extract, total tanshinone contains
Amount is 10-20%.Described Herba Apocyni veneti extract general flavone content is 30-50%.
After described each raw material is weighed according to quantity, conventionally add adjuvant conventional on pharmaceutics and be prepared as powder,
0.5g/ bag.Embodiment 2
A kind of health product being improved immunity of organisms and anti-fatigue effect by regulation and control content of nitric oxide technology, it is
It is made up of the raw material of following weight portion: L-arginine 150 parts, citrulline 30 parts, taurine 15 parts, vitamin C 0.8 part, dimension are raw
Element E 0.5 part, 2 parts of folic acid, Herba Apocyni veneti extract 20 parts, Radix Salviae Miltiorrhizae extract 30 parts.In described Radix Salviae Miltiorrhizae extract, total tanshinone contains
Amount is 10-20%.Described Herba Apocyni veneti extract general flavone content is 30-50%.
After described each raw material is weighed according to quantity, conventionally add adjuvant conventional on pharmaceutics and be prepared as tablet,
0.4g/ sheet.Embodiment 3
A kind of health product being improved immunity of organisms and anti-fatigue effect by regulation and control content of nitric oxide technology, it is
It is made up of the raw material of following weight portion: L-arginine 130 parts, citrulline 20 parts, taurine 12 parts, vitamin C 0.5 part, dimension are raw
Element E 0.4 part, 1.5 parts of folic acid, Herba Apocyni veneti extract 15 parts, Radix Salviae Miltiorrhizae extract 25 parts.Total tanshinone in described Radix Salviae Miltiorrhizae extract
Content is 10-20%.Described Herba Apocyni veneti extract general flavone content is 30-50%.
After described each raw material is weighed according to quantity, conventionally add adjuvant conventional on pharmaceutics and be prepared as capsule
Agent, 0.4g/ grain.
Embodiment 4
A kind of health product being improved immunity of organisms and anti-fatigue effect by regulation and control content of nitric oxide technology, it is
It is made up of the raw material of following weight portion: L-arginine 120 parts, citrulline 25 parts, taurine 10 parts, vitamin C 0.6 part, dimension are raw
Element E 0.4 part, 1.2 parts of folic acid, Herba Apocyni veneti extract 18 parts, Radix Salviae Miltiorrhizae extract 24 parts.Total tanshinone in described Radix Salviae Miltiorrhizae extract
Content is 10-20%.Described Herba Apocyni veneti extract general flavone content is 30-50%.
After described each raw material is weighed according to quantity, conventionally add adjuvant conventional on pharmaceutics and be prepared as pill,
0.4g/ ball.Immunologic function of the present invention is tested
Impact on Phagocytosis By The Peritoneal Macrophages In Mice
Taking mice 80, body weight, at 20-25g, is uniformly divided into 8 groups at random, and test group 1-4 group is respectively by above-described embodiment 1-
4 health product prepared mix in normal diet, and consumption is that 20mg/10g/day (is equivalent to adult's per kg body weight per day recommend to take the photograph
Enter 20 times of amount)；Compareing 1 group is to be mixed in mice normal diet by certain brand Nai Woke powder existing for market, and consumption is 16.7mg/
10g/day (is equivalent to 20 times of adult's per kg body weight per day recommended intake)；Compare 2 groups and use same method feeding and examination
Test the group single Radix Salviae Miltiorrhizae extract with dosage；Compareing 3 groups uses same method feeding and test group with the single Herba Apocyni veneti of dosage
Extract；Compare 4 groups of starch being blank group and i.e. mixing same dosage in normal diet, every day feeding 1 time, continuous 7 days.
1h after being administered in last 1 time, every mouse peritoneal injects 5% chicken red blood cell suspension 0.4ml, and after to chicken red blood cell, 4h puts to death
Mice, surveys Phagocytosis By The Peritoneal Macrophages In Mice by the chicken red blood cell method in tradition toxicology test.Result of the test is shown in Table 1.
The table 1 impact on normal Phagocytosis By The Peritoneal Macrophages In Mice
| Group | Number of animals/only | Phagocytic percentage % | Phagocytic index |
| Test 1 group | 10 | 71.3±3.2 | 0.92±0.63 |
| Test 2 groups | 10 | 73.3±4.2 | 0.95±0.62 |
| Test 3 groups | 10 | 75.4±2.9 | 0.99±0.71 |
| Test 4 groups | 10 | 73.5±3.5 | 0.97±0.88 |
| Compare 1 group | 10 | 70.2±4.0 | 0.91±0.69 |
| Compare 2 groups | 10 | 56.9±3.5 | 0.62±0.73 |
| Compare 3 groups | 10 | 53.2±4.1 | 0.69±0.51 |
| Compare 4 groups | 10 | 40.2±3.2 | 0.60±0.49 |
The impact that normal mouse hemolysin is formed
Mouse species number, be grouped, be administered all the same, in being administered the 1st day, every Mus lumbar injection 5% chicken red blood cell physiology salt
Aqueous suspension 0.2ml carries out immunity, and after last after medicine 2h, mouse orbit takes blood, examines by serum hemolysin spectrophotometric
Survey method surveys hemolysin formational situation.
The impact that normal mouse hemolysis plaque is formed
Mouse species number, it is grouped, is administered and immunity is all the same, 2h after last administration, mice is taken off cervical vertebra and puts to death,
Dissect and take out spleen, two mouse spleens are put together and is homogenized, by Traditional pharmacological testing inspection hemolysis plaque by homogenizer
Method detects this test formational situation.
The impact that normal mouse lymphocyte is converted
Mouse species number, be grouped, be administered all the same, in first 3 days be administered, every mice intramuscular injection every day plant blood clotting
Element 8mg/kg, 2h after last administration, mice cuts tail and takes blood, push jack, and Switzerland's dye liquor dyeing, with oil sem observation periphery stranguria with blood
Bar cell transformation rate.Result of the test is shown in Table 2.
The table 2 impact on the conversion of normal mouse hemolysin, hemolysis plaque formation and lymphocyte
The data of contrast Tables 1 and 2, we are it is found that compared with blank group, the health product of the present invention are to mice
Peritoneal Macrophage Phagocytosis, mice hemolysin, hemolysis plaque are formed and the conversion aspect of lymphocyte is respectively provided with preferably
Immune effect.Compared with comparison 2 and comparison 3, health product of the present invention combination has more preferable immunologic function than single raw material；Comparison
Although group 1 also has preferable immune effect, but the present invention is after adding Radix Salviae Miltiorrhizae extract and Herba Apocyni veneti extract, its entirety
Immune effect significantly improves, and this is mainly due to reasonable raw material proportioning of the present invention, synergism between each raw material, Radix Salviae Miltiorrhizae and Herba Apocyni veneti
Addition significantly improve kidney and the hepatic levels of body, from traditional Chinese medical science angle liver and kidney tonifying, significantly improve exempting from of body
Epidemic disease ability.
Anti-fatigue effect is tested
This experiment is designed with reference to " function of health food assessment process and the method for inspection ".
Experiment material
Laboratory animal: three monthly age kunming mices 70 (purchased from Hebei Medical University's biotic experiment center), body weight 18-22g.
Laboratory sample: the sample that embodiment 3 prepares.
Dosage choice and sample treatment: experiment sets blank group, matched group 1 (Radix Salviae Miltiorrhizae extract), matched group 2 (are spreaded out
Nettle extract), matched group 3 (certain brand Nai Woke powder product commercially available) and experimental group basic, normal, high three dosage groups, the most often groups
Each 10.Each tested group of medicine is prepared as powder, is then equipped to solution with the consumption distilled water of every mice 0.2ml every day
To mouse stomach, experimental group each mice gavage every day (low dosage: 2mg/10g/day, middle dosage: 10mg/10g/day, high agent
Amount: 100mg/10g/day, is respectively equivalent to 2 times of human body recommended amounts, 10 times, 100 times), matched group 1,2,3 is respectively adopted people
Test for 10 times of body recommended dose, be carried out continuously 30 days, extend to 45 days if desired.
Key instrument and reagent: swimming trunk (size about 50cm × 50cm × 40cm), electronic balance, sheet lead；Diameter 1cm,
The Glass rod of long 25cm, after sand papering, upper end is fixed on plank and makes pole-climbing frame；Multi-functional microplate reader (synergy
Biotech), centrifuge (Thermo), Lactic acid Kit (100T/48 sample, Nanjing is built up), lactic dehydrogenase enzyme reagent kit (100T/
48 samples, Nanjing is built up), glycogen test kit (100T/48 sample, Nanjing is built up).
Experimental technique: by Loaned swimming test, pole-jump test, blood lactase acid determination experiment, measuring content of lactic dehydrogenase
Test, hepatic glycogen and muscle glycogen measure and carry out assessment of function.
Experimental result:
1, the product of the present invention impact on the mice burden swimming time.
The most direct tired and the most objectively performance is the decline of exercise tolerance, and swimming time is made all the time
For reflecting the important indicator of exercise tolerance.Concrete outcome is as shown in table 3.
Table 3 walking weight load experimental result
From data in table 3, mouse swimming power compared with blank group of gavage high, medium and low dosage group exhausts the time
Having increased, and the basic, normal, high dosage group increase time presents the trend gradually risen, this is from macroscopically embodying the present invention
Health product have good anti-fatigue ability.And compared with blank, comparison 1 and comparison 2 swimming time amplification are less, and compare
3 compare with blank group, and the swimming time of mice has extended, but after extending, swimming time is all not as high dose in the present invention
The mice swimming time of group is long, and the present invention tests the swimming time amplification time amplification than 3 matched groups of high dose group
Summation also want big, each component synergism of this explanation present invention, than single any component or appoint the simple of several components
Combined effect will be got well, and achieves unforeseeable effect, has the effect of significant resisting fatigue.
2, the product of the present invention impact on the mice pole-climbing time
The raising of exercise tolerance is that anti-fatigue ability strengthens the strongest macro manifestations, and the length of pole-climbing time can be reacted
Animal quiet firmly time tired degree.Concrete outcome is as shown in table 4.
Table 4 Grasping clubglass test result
As can be seen from Table 4, compared with blank group, basic, normal, high three dosage group pole-climbing times all rise appreciably,
Illustrate that health product of the present invention have good antifatigue effect.Compare 1,2,3 groups compared with blank, all have certain resisting fatigue
Effect, but the product that its resisting fatigue effect does not all have the present invention is good, and this is that the synergism of each component due to the present invention is notable.
3, the product of the present invention impact on Mouse Blood lactic acid
Blood lactase acid is an important indicator of evaluation organism fatigue degree, and it is glucolytic product, to glycolysis energy supply
System is very sensitive.Under anaerobic environment, body still using glycogen as energy substance, except that, carbohydrate metabolism mistake now
Journey is anerobic glycolysis, and the energy that anerobic glycolysis not only produces is considerably less, and its product lactic acid is cause organism fatigue sense straight
Connect the factor, so by the lactic acid content of body after motion, we can judge that body is to the picked-up of oxygen and Utilization ability.
Table 5 blood lactase acid measurement result
As shown in Table 5, mice blank group blood lactase acid level after exercise is higher, is administered low dosage, middle dosage, high agent
Amount group mice blood lactase acid level compared with matched group significantly reduces, and this shows that the health product of the present invention can be by minimizing campaign
The generation of lactic acid, reaches the effect of delay fatigue.Compare 1,2,3 groups of blood lactase acid levels to compare with blank group and dropped
Low, but overall reducing effect is good not as experimental group dose effect of the present invention.
The antihypertensive function of health product of the present invention is carried out clinical trial applied research
Clinical data: randomly selecting 300 example hyperpietics, the maleest 180 examples, female 120 example, age distribution is at 10-75
In year, patient takes the health product of the embodiment of the present invention 3 preparation, three times a day, each 2, observes clinic after taking continuously one month
Effect.
Diagnostic criteria: shrinking pressure equal to or higher than 140mmHg, diastolic pressure equal to or higher than 90mmHg, both have a core
Real, can make a definite diagnosis.
Curative effect determinate standard: (1) is effective: diastolic pressure declines more than 10mmHg, and reaches normal range, though or diastolic pressure not
Reach normal range but declined 20mmHg or more than；It is (2) effective: diastolic pressure declines not as good as 10mmHg, but has reached normal range,
Though or diastolic pressure does not reaches normal range but declined 10-19mmHg, or shrinking more than drops 30mmHg；(3) invalid: to shrink pressure
It is not up to above-mentioned standard with diastolic pressure.
Therapeutic outcome is added up: result shows by clinical observation, the most effective example 155 example, accounts for 51.7%；Effectively example 124 example,
Account for 41.3%；Invalid example 21 example, accounts for 7%；Total effective rate reaches 93%.The patient of all uses health product of the present invention is all without any
Untoward reaction and malaise symptoms.
Claims (5)
1. health product for immunity of organisms and anti-fatigue effect, its feature is improved by regulation and control content of nitric oxide technology
Being, it is made up of the raw material of following weight portion: L-arginine 100-150 part, citrulline 10-30 part, taurine 8-15 part,
Vitamin C 0.3-0.8 part, vitamin E 0.3-0.5 part, folic acid 1-2 part, Herba Apocyni veneti extract 10-20 part, Radix Salviae Miltiorrhizae extract
20-30 part.
Raising immunity of organisms the most according to claim 1 and the health product of anti-fatigue effect, it is characterised in that it be by
The raw material of following weight portion is made: L-arginine 130 parts, citrulline 20 parts, taurine 12 parts, vitamin C 0.5 part, vitamin
E 0.4 part, 1.5 parts of folic acid, Herba Apocyni veneti extract 15 parts, Radix Salviae Miltiorrhizae extract 25 parts.
The health product improving immunity of organisms and anti-fatigue effect the most according to claim 1 and 2, it is characterised in that
In described Radix Salviae Miltiorrhizae extract, total tanshinone content is 10-20%.
The health product improving immunity of organisms and anti-fatigue effect the most according to claim 1 and 2, it is characterised in that
Described Herba Apocyni veneti extract general flavone content is 30-50%.
Raising immunity of organisms the most according to claim 1 and 2 and the health product of anti-fatigue effect, it is characterised in that institute
State after each raw material weighs according to quantity, conventionally add adjuvant conventional on pharmaceutics be prepared as capsule, tablet, powder or
Pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610565218.0A CN106074696A (en) | 2016-07-18 | 2016-07-18 | A kind of health product being improved immunity of organisms and anti-fatigue effect by regulation and control content of nitric oxide technology |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610565218.0A CN106074696A (en) | 2016-07-18 | 2016-07-18 | A kind of health product being improved immunity of organisms and anti-fatigue effect by regulation and control content of nitric oxide technology |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106074696A true CN106074696A (en) | 2016-11-09 |
Family
ID=57220626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610565218.0A Pending CN106074696A (en) | 2016-07-18 | 2016-07-18 | A kind of health product being improved immunity of organisms and anti-fatigue effect by regulation and control content of nitric oxide technology |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106074696A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106420817A (en) * | 2016-11-22 | 2017-02-22 | 张标 | Health care product capable of enhancing body immunity and relieving fatigue |
| CN109846046A (en) * | 2019-04-10 | 2019-06-07 | 山东汉泰生物科技有限公司 | A kind of mannose-amino acid complex improving immunity |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104026563A (en) * | 2013-03-07 | 2014-09-10 | 山东明仁福瑞达制药股份有限公司 | Composition having muscle power fatigue alleviating and anoxic tolerance improving effects, and preparation method thereof |
-
2016
- 2016-07-18 CN CN201610565218.0A patent/CN106074696A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104026563A (en) * | 2013-03-07 | 2014-09-10 | 山东明仁福瑞达制药股份有限公司 | Composition having muscle power fatigue alleviating and anoxic tolerance improving effects, and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 邵继萍: "丹参提取物对持续性训练下小鼠骨骼肌的抗疲劳作用", 《赤峰学院学报（自然科学报）》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106420817A (en) * | 2016-11-22 | 2017-02-22 | 张标 | Health care product capable of enhancing body immunity and relieving fatigue |
| CN109846046A (en) * | 2019-04-10 | 2019-06-07 | 山东汉泰生物科技有限公司 | A kind of mannose-amino acid complex improving immunity |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2599490B1 (en) | Anti-fatigue composition, formulation and use thereof | |
| CN103750339B (en) | Saussurea involucrate culture health-care food and application thereof | |
| JP2018502079A (en) | Eurycoma longifolia extract and its use in enhancing and / or stimulating the immune system | |
| CN107691952A (en) | A kind of resisting kinetic fatigue, the composition for promoting postexercise recovery and preparation method thereof | |
| CN104026563A (en) | Composition having muscle power fatigue alleviating and anoxic tolerance improving effects, and preparation method thereof | |
| JP2024528055A (en) | Use of a nucleotide mixture in the preparation of a formulation for preventing or alleviating age-related sarcopenia | |
| CN107343658A (en) | A kind of antifatigue SOD oyster peptides complex capsule and preparation method thereof | |
| CN106074696A (en) | A kind of health product being improved immunity of organisms and anti-fatigue effect by regulation and control content of nitric oxide technology | |
| KR101689259B1 (en) | Composition having effects of preventing or recovering fatigue or stress | |
| CN1785054A (en) | Health-care food having anti-oxidation function and its prepn. method | |
| CN102008083B (en) | Health food for alleviating physical fatigue and removing chloasma | |
| CN106420817A (en) | Health care product capable of enhancing body immunity and relieving fatigue | |
| CN103816278A (en) | Composition for reducing blood sugar and application thereof | |
| CN106176929A (en) | A kind of health product being improved immunity of organisms and antihypertensive function by regulation and control content of nitric oxide technology | |
| CN108935694A (en) | A kind of healthcare goat milk powder and preparation method thereof with antifatigue simultaneous void of enriching blood | |
| CN104026568A (en) | Health care product composition | |
| CN108371326B (en) | Functional composition for reducing blood sugar | |
| US20180055848A1 (en) | Combination of Albuterol and Caffeine as Synergistic Treatment for Obesity or Sarcopenia | |
| CN108904596B (en) | Composition with memory improving effect | |
| KR100880537B1 (en) | Composition comprising cantaloupe melon extract and gliadin for improving ability of brain | |
| KR20210096121A (en) | Antidiabetic activity of neem extract and synergistic combination of urolitin A and B | |
| CN109170914A (en) | A kind of anti-fatigue health-caring composition and preparation method thereof | |
| CN107259031A (en) | A kind of blood pressure depressing health tea | |
| CN106109541A (en) | A kind of health product improving immunity of organisms, resisting fatigue | |
| DK2686004T3 (en) | COMPOSITION COMPREHENSIVE DIAMINOXIDASE TO USE FOR TREATMENT OR PREVENTION OF FIBROMYALGY OR CHRONIC TIRE SYNDROME |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170519 Address after: Qing Ping Road Qingpu District Xujing town Shanghai City Luzhou 201700 No. 2008 floor 10 room 1025 Applicant after: SHANGHAI NO-TOP BIOTECHNOLOGY CO., LTD. Address before: 200030 Shanghai city Xuhui District Yunjin Road No. 500 Green Exchange Center B building 17 floor Applicant before: Zhang Biao |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190117 Address after: 511442 Room 602, 4 Building, 383 North Panyu Avenue, Nancun Town, Panyu District, Guangzhou City, Guangdong Province Applicant after: Guangzhou Sansan Medical Biotechnology Co., Ltd. Address before: Room 1025, 10th floor, 2008 Luqingping Road, Xujing Town, Qingpu District, Shanghai Applicant before: SHANGHAI NO-TOP BIOTECHNOLOGY CO., LTD. |
|
| TA01 | Transfer of patent application right | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161109 |
|
| RJ01 | Rejection of invention patent application after publication |